Crizanlizumab

Active ingredient description

Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands including P-selectin glycoprotein ligand 1.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
B06AX01 B Blood and blood forming organs → B06 Other hematological agents → B06A Other hematological agents → B06AX Other hematological agents
Discover more medicines within B06AX01

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
ADAKVEO Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

External identifiers

CAS Substance: 1690318-25-2
DrugBank Drug: DB15271
RxNorm Ingredient: 2262279
SNOMED-CT Concept: 830160007
Crizanlizumab (substance)
UNII Identifier: L7451S9126
CRIZANLIZUMAB

Medicines

Crizanlizumab is an active ingredient of these brands:

United States (US)

Austria (AT)

Brazil (BR)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Lithuania (LT)

Poland (PL)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.